Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Market Report; Launched via MarketResearchReports.com

As per NAVADHI Market Research, the global pharmaceutical industry will we worth USD 1.57 trillion by 2023.

Gilead Sciences, Inc. (Gilead) is a U.S. based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases.

Gilead Sciences registered profit in the fourth quarter from a loss last year, helped by a push in income taxes provision.

Company's 2018 Revenue declined 2.6% to USD 5.8 billion. The results reflected by lower product sales in Europe and in other regions. Chronic hepatitis C virus franchise sales plunged 50.8% due to lower average selling price and lower sales volume of Harvoni and Epclusa across all major markets as a result of increased generic competition and the lower patient engagement.

For the fourth quarter, R&D expenses increased by 69.6% Y-O-Y. This was primarily due to an impairment charge related to in-process R&D for multiple myeloma treating program, up-front collaboration expenses and higher investments to support the growth of Gilead’s business following the acquisition of Kite.

Spanning over 30 pages and 18 exhibits, “Gilead Sciences, Inc. - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.

Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report

- This report provides detailed information about Gilead Sciences, Inc. including value chain analysis, financial performance, business strategy and SWOT analysis.

- The report identifies the growth drivers and inhibitors for global pharmaceutical market.

- This report provides information about current and future trends for global pharmaceutical market.

For more details visit: https://www.marketresearchreports.com/navadhi/gilead-sciences-inc-company-snapshot-swot-analysis

Browse more on   Pharma andHealthcare Market Research Reports

Read our Interactive Market Research Blog

About MarketResearchReports.com

MarketResearchReports.com is world's largest store offering quality marketresearch, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

About NAVADHI Market Research Pvt Ltd.

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

Press Contact:
Mr. Sudeep Chakravarty
Director - Operations
MarketResearchReports.com

USA: +1-302-703-9904

Contact us for your market research requirements: https://www.marketresearchreports.com/contact

AbbVie Inc - Company Snapshot & SWOT Analysis Market Report; Launched via MarketResearchReports.com

As per NAVADHI Market Research, the global pharmaceutical industry will we worth USD 1.57 trillion by 2023.

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. The company operates in more than 75 countries.

AbbVie’s products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neurology, with additional targeted investment in cystic fibrosis and women’s health.

AbbVie Inc. reported revenue of USD 32.733 billion for the FY 2018 which saw an increase of 16% compared to FY 2017.

Company's global sales were impacted by the launch of several direct biosimilar drugs. These drugs are launched at much cheaper price anticipated by AbbVie resulting decline in sales in Europe and other international markets.

AbbVie Inc. registered highest revenue from immunology (Humira) at USD 19.936 billion. Humira continue to perform better in the U.S. market, drug sales are expected to rise approximately 7% in 2019, which is less than growth of 10% in 2018 due to lighter price contribution for the year.

Spanning over 27 pages and 10 exhibits, “AbbVie Inc - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.

Scope of the AbbVie Inc - Company Snapshot & SWOT Analysis Report

- This report provides detailed information about AbbVie Inc including value chain analysis, financial performance, business strategy and SWOT analysis.

- The report identifies the growth drivers and inhibitors for global pharmaceutical market.

- This report provides information about current and future trends for global pharmaceutical market.

For more details visit: https://www.marketresearchreports.com/navadhi/abbvie-inc-company-snapshot-swot-analysis

Browse more on   Pharma andHealthcare Market Research Reports

Read our Interactive Market Research Blog

About NAVADHI Market Research Pvt Ltd.

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

Global Colposcopy Market is expected to grow at a CAGR of 8.3% and to reach 890 million USD in 2023, from 600 million USD in 2017

Colposcopy is a medical diagnostic procedure to examine an illuminated, magnified view of the cervix and the tissues of the vagina and vulva. Many premalignant lesions and malignant lesions in these areas have discernible characteristics which can be detected through the examination. It is done using a colposcopy, which provides an enlarged view of the areas, allowing the colposcopies to visually distinguish normal from abnormal appearing tissue and take directed biopsies for further pathological examination. The main goal of colposcopy is to prevent cervical cancer by detecting precancerous lesions early and treating them.

Scope of the Report:

This report focuses on the Colposcopy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Colposcopy is a medical diagnostic procedure to examine an illuminated, magnified view of the cervix and the tissues of the vagina and vulva. Many premalignant lesions and malignant lesions in these areas have discernible characteristics which can be detected through the examination. It is done using a colposcopy, which provides an enlarged view of the areas, allowing the colposcopies to visually distinguish normal from abnormal appearing tissue and take directed biopsies for further pathological examination. The main goal of colposcopy is to prevent cervical cancer by detecting precancerous lesions early and treating them.

The worldwide market for Colposcopy is expected to grow at a CAGR of roughly 8.3% over the next five years, will reach 890 million US$ in 2023, from 600 million US$ in 2017.

Market Segment by Manufacturers, this report covers

• Leisegang
• Welch Allyn
• Philips
• Olympus
• Zeiss
• Centrel
• OPTOMIC
• MedGyn
• Ecleris
• DYSIS Medical
• Lutech
• ATMOS
• Wallach
• Beijing SWSY
• EDAN Instruments
• Seiler
• Xuzhou Zhonglian
• STAR
• Kernel

Market Segment by Regions, regional analysis covers

• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia etc.)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

• Electronic Colposcopy
• Optical Colposcopy

Market Segment by Applications, can be divided into

• Physical Examination
• Cervical Cancer Diagnostic
• Other

There are 15 Chapters to deeply display the global Colposcopy market.

Chapter 1, to describe Colposcopy Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Colposcopy, with sales, revenue, and price of Colposcopy, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Colposcopy, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Colposcopy market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Colposcopy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Spanning over 151 pages “Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Colposcopy Market 2018, Forecast to 2023” report covers Market Overview, Manufacturers Profiles, Global Colposcopy Market Competition, by Manufacturer, Global Colposcopy Market Analysis by Regions, North America Colposcopy by Countries, Type, Application and Manufacturers, Europe Colposcopy by Countries, Type, Application and Manufacturers, Asia-Pacific Colposcopy by Countries, Type, Application and Manufacturers, South America Colposcopy by Countries, Type, Application and Manufacturers, Middle East and Africa Colposcopy by Countries, Type, Application and Manufacturers, Global Colposcopy Market Segment by Type, Global Colposcopy Market Segment by Application, Colposcopy Market Forecast (2018-2023), Sales Channel, Distributors, Traders and Dealers, Research Findings and Conclusion, Appendix.

Please visit this link for more details: https://www.marketresearchreports.com/gir/global-north-america-europe-asia-pacific-south-america-middle-east-and-africa-colposcopy-market

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

For related reports please visit: https://www.marketresearchreports.com/search/site/Colposcopy

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2018 Market Report; Launched via MarketResearchReports.com

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2018 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Paroxysmal Nocturnal Hemoglobinuria development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Paroxysmal Nocturnal Hemoglobinuria

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Paroxysmal Nocturnal Hemoglobinuria

The report assesses the active Paroxysmal Nocturnal Hemoglobinuria pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report

• The report provides a snapshot of the pipeline development for the Paroxysmal Nocturnal Hemoglobinuria
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Paroxysmal Nocturnal Hemoglobinuria
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Paroxysmal Nocturnal Hemoglobinuria
• The report also covers the dormant and discontinued pipeline projects related to the Paroxysmal Nocturnal Hemoglobinuria

Reasons to Buy

• Establish comprehensive understanding of the pipeline activity across this Paroxysmal Nocturnal Hemoglobinuria to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Paroxysmal Nocturnal Hemoglobinuria therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Spanning over 50 pages “Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2018” report covers Report Introduction, Paroxysmal Nocturnal Hemoglobinuria Overview, Pipeline Therapeutics, Comparative Analysis, Products in Clinical Stage, Products in Pre-Clinical and Discovery Stage, Therapeutic Assessment, Inactive Products, Appendix. This report Covered Companies - Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Amgen Inc, Apellis Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, ISU ABXIS Co Ltd, Novartis AG, NovelMed Therapeutics Inc, Omeros Corp, Ra Pharmaceuticals Inc, & list continues...

Please visit this link for more details: http://mrr.cm/U8w

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Partial Seizure - Pipeline Insight, 2018 - Visit at - http://mrr.cm/U8i

Pancreatic Endocrine Tumor - Pipeline Insight, 2018 - Visit at - http://mrr.cm/UWA

Pleural Effusion - Pipeline Insight, 2018 Market Report; Launched via MarketResearchReports.com

Pleural Effusion - Pipeline Insight, 2018 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Pleural Effusion development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Pleural Effusion

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Pleural Effusion

The report assesses the active Pleural Effusion pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report

• The report provides a snapshot of the pipeline development for the Pleural Effusion
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Pleural Effusion
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Pleural Effusion
• The report also covers the dormant and discontinued pipeline projects related to the Pleural Effusion

Reasons to Buy

• Establish comprehensive understanding of the pipeline activity across this Pleural Effusion to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Pleural Effusion therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Spanning over 50 pages “Pleural Effusion - Pipeline Insight, 2018” report covers Report Introduction, Pleural Effusion Overview, Pipeline Therapeutics, Comparative Analysis, Products in Clinical Stage, Products in Pre-Clinical and Discovery Stage, Therapeutic Assessment, Inactive Products, Appendix. This report Covered Companies - Advantagene Inc, Genelux Corp, Shenzen SiBiono GeneTech Co Ltd, Regulonm, Lung Therapeutics, & list continues…

Please visit this link for more details: http://mrr.cm/ULr

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Polycythemia - Pipeline Insight, 2018 - Visit at - http://mrr.cm/UKp

Polymyositis - Pipeline Insight, 2018 - Visit at - http://mrr.cm/UKG